Protagonist Therapeutics is a Nasdaq-listed pharmaceutical preparations company with a market capitalization of about $9.44 billion, operating in the Biotech Therapeutics theme. The stock has outperformed the S&P over both three months and twelve months, and technical measures classify the stock in a confirmed uptrend and Weinstein Stage 2 continuation.
Financial results have been uneven. Revenue shows a lumpy pattern: a large quarter of $254.953 million in 2024Q1, several quarters of single-digit millions, then a recovery to $56.368 million in 2026Q1, which was roughly a 99% year-over-year increase for that quarter. GAAP diluted EPS has been volatile as well, with GAAP profits in some quarters (GAAP diluted EPS of $3.26 in 2024Q1 and $2.29 in 2026Q2) and losses in others; metrics indicate neither revenue nor EPS are accelerating consistently.
The company meets a number of leadership criteria for the Biotech Therapeutics theme: it passed multiple screening gates including minimum price and volume thresholds, has a high theme score, and shows strong relative strength versus SPY (excess return +45.3% over three months, +122.8% over twelve months). Institutional interest is broad, with 485 reporting institutions holding about 1.20% of shares, although accumulation metrics are mixed.
Why now
The technical picture and relative performance make this a timely name to watch: price sits above the 50-day and 200-day moving averages, seven of seven trend checks have passed, and the stock has materially outperformed the market recently; however, no verified fresh breakout or 9/21-day EMA add setup is present, so the setup is constructive but not currently actionable.
The setup
Last close was $145.94, above the 50-day SMA ($141.48) and the 200-day SMA ($106.37), while the short-term EMAs sit slightly above price (9-day EMA 147.57, 21-day EMA 147.35) and the stock is about 1% below those EMAs. Weinstein classifies the stock as Stage 2 — continuation, and seven of seven trend checks passed. Entry readiness is labeled 'watch' because there is no fresh verified breakout or EMA add; distance from the 9-day EMA is -1.1% and from the 21-day EMA is -0.96%.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (12 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $4.79 (+334%) · FY'27E $-0.20 (-104%) — 12 analysts
Risks
Revenue and earnings are lumpy and unpredictable, with one very large quarter followed by mostly modest sales, which makes forward revenue visibility limited; GAAP diluted EPS has been volatile and not consistently positive. Technically, the stock is in an established uptrend but sits just below short-term EMAs and lacks a fresh breakout, so the uptrend could stall. Accumulation measures are mixed (50-day up/down volume ratio 0.83 and a small average top-holder position reduction), which could leave the stock vulnerable during broader biotech weakness.
Framework fit
CANSLIM
4/7- CCurrent quarterly GAAP EPS growth ≥ 25%-106%✕
- AAnnual GAAP EPS growth ≥ 25%-148%✕
- NNew highs — within 15% of 52-week high-7.99%✓
- SSupply/demand — up-day volume leads0.83x✕
- LLeader — outperforming the S&P 500+38% 6m✓
- IInstitutional sponsorshipmodel score 7/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
7/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price is above a rising 30-week proxy, with the 200-day line used as a separate confirmation.